nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimetrexate—Electrolyte imbalance—Diclofenamide—glaucoma	0.0626	0.0728	CcSEcCtD
Trimetrexate—Electrolyte imbalance—Methazolamide—glaucoma	0.0576	0.0671	CcSEcCtD
Trimetrexate—Electrolyte imbalance—Acetazolamide—glaucoma	0.0399	0.0464	CcSEcCtD
Trimetrexate—Convulsion—Physostigmine—glaucoma	0.0227	0.0265	CcSEcCtD
Trimetrexate—Hyponatraemia—Carbachol—glaucoma	0.0186	0.0216	CcSEcCtD
Trimetrexate—DHFR—Metabolism of folate and pterines—MTHFR—glaucoma	0.0178	0.126	CbGpPWpGaD
Trimetrexate—Vomiting—Physostigmine—glaucoma	0.0136	0.0159	CcSEcCtD
Trimetrexate—Nausea—Physostigmine—glaucoma	0.0127	0.0148	CcSEcCtD
Trimetrexate—Hyponatraemia—Acetazolamide—glaucoma	0.0121	0.0141	CcSEcCtD
Trimetrexate—DHFR—Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation—NOS3—glaucoma	0.00987	0.0701	CbGpPWpGaD
Trimetrexate—Confusional state—Diclofenamide—glaucoma	0.0094	0.0109	CcSEcCtD
Trimetrexate—Thrombocytopenia—Diclofenamide—glaucoma	0.00913	0.0106	CcSEcCtD
Trimetrexate—Convulsion—Methazolamide—glaucoma	0.00911	0.0106	CcSEcCtD
Trimetrexate—DHFR—Metabolism of nitric oxide—CAV1—glaucoma	0.00904	0.0641	CbGpPWpGaD
Trimetrexate—Confusional state—Levobunolol—glaucoma	0.00903	0.0105	CcSEcCtD
Trimetrexate—Confusional state—Methazolamide—glaucoma	0.00866	0.0101	CcSEcCtD
Trimetrexate—Fatigue—Diclofenamide—glaucoma	0.00804	0.00936	CcSEcCtD
Trimetrexate—Feeling abnormal—Diclofenamide—glaucoma	0.00768	0.00894	CcSEcCtD
Trimetrexate—Fatigue—Methazolamide—glaucoma	0.0074	0.00862	CcSEcCtD
Trimetrexate—Feeling abnormal—Levobunolol—glaucoma	0.00738	0.0086	CcSEcCtD
Trimetrexate—Body temperature increased—Diclofenamide—glaucoma	0.00737	0.00858	CcSEcCtD
Trimetrexate—Asthenia—Metipranolol—glaucoma	0.00734	0.00855	CcSEcCtD
Trimetrexate—Body temperature increased—Carbachol—glaucoma	0.00719	0.00837	CcSEcCtD
Trimetrexate—DHFR—One Carbon Metabolism—MTHFR—glaucoma	0.00719	0.051	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Methazolamide—glaucoma	0.00707	0.00823	CcSEcCtD
Trimetrexate—DHFR—Metabolism of nitric oxide—NOS3—glaucoma	0.00684	0.0485	CbGpPWpGaD
Trimetrexate—Asthenia—Carteolol—glaucoma	0.0068	0.00792	CcSEcCtD
Trimetrexate—Body temperature increased—Methazolamide—glaucoma	0.00679	0.0079	CcSEcCtD
Trimetrexate—Asthenia—Diclofenamide—glaucoma	0.00669	0.00779	CcSEcCtD
Trimetrexate—Pruritus—Diclofenamide—glaucoma	0.0066	0.00768	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Betaxolol—glaucoma	0.00656	0.00763	CcSEcCtD
Trimetrexate—DHFR—Trans-sulfuration and one carbon metabolism—MTHFR—glaucoma	0.00646	0.0458	CbGpPWpGaD
Trimetrexate—Rash—Metipranolol—glaucoma	0.00645	0.00751	CcSEcCtD
Trimetrexate—Dermatitis—Metipranolol—glaucoma	0.00645	0.00751	CcSEcCtD
Trimetrexate—Asthenia—Levobunolol—glaucoma	0.00643	0.00748	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Betaxolol—glaucoma	0.00642	0.00747	CcSEcCtD
Trimetrexate—Pruritus—Levobunolol—glaucoma	0.00634	0.00738	CcSEcCtD
Trimetrexate—Convulsion—Acetazolamide—glaucoma	0.00631	0.00734	CcSEcCtD
Trimetrexate—DHFR—Fluoropyrimidine Activity—MTHFR—glaucoma	0.0063	0.0447	CbGpPWpGaD
Trimetrexate—Asthenia—Methazolamide—glaucoma	0.00616	0.00717	CcSEcCtD
Trimetrexate—Nausea—Metipranolol—glaucoma	0.00608	0.00708	CcSEcCtD
Trimetrexate—Confusional state—Acetazolamide—glaucoma	0.00599	0.00697	CcSEcCtD
Trimetrexate—Vomiting—Diclofenamide—glaucoma	0.00593	0.0069	CcSEcCtD
Trimetrexate—Pruritus—Latanoprost—glaucoma	0.00588	0.00684	CcSEcCtD
Trimetrexate—Rash—Diclofenamide—glaucoma	0.00588	0.00684	CcSEcCtD
Trimetrexate—Thrombocytopenia—Acetazolamide—glaucoma	0.00582	0.00677	CcSEcCtD
Trimetrexate—Vomiting—Carbachol—glaucoma	0.00579	0.00673	CcSEcCtD
Trimetrexate—Rash—Carbachol—glaucoma	0.00574	0.00668	CcSEcCtD
Trimetrexate—Dermatitis—Carbachol—glaucoma	0.00573	0.00667	CcSEcCtD
Trimetrexate—Fatigue—Apraclonidine—glaucoma	0.00573	0.00667	CcSEcCtD
Trimetrexate—Nausea—Carteolol—glaucoma	0.00563	0.00656	CcSEcCtD
Trimetrexate—Nausea—Diclofenamide—glaucoma	0.00554	0.00645	CcSEcCtD
Trimetrexate—Confusional state—Dorzolamide—glaucoma	0.00549	0.00639	CcSEcCtD
Trimetrexate—Feeling abnormal—Apraclonidine—glaucoma	0.00547	0.00637	CcSEcCtD
Trimetrexate—Vomiting—Methazolamide—glaucoma	0.00546	0.00635	CcSEcCtD
Trimetrexate—Rash—Methazolamide—glaucoma	0.00541	0.0063	CcSEcCtD
Trimetrexate—Dermatitis—Methazolamide—glaucoma	0.00541	0.00629	CcSEcCtD
Trimetrexate—Nausea—Carbachol—glaucoma	0.0054	0.00629	CcSEcCtD
Trimetrexate—Nausea—Levobunolol—glaucoma	0.00532	0.0062	CcSEcCtD
Trimetrexate—Rash—Latanoprost—glaucoma	0.00524	0.0061	CcSEcCtD
Trimetrexate—Dermatitis—Latanoprost—glaucoma	0.00523	0.00609	CcSEcCtD
Trimetrexate—Confusional state—Pilocarpine—glaucoma	0.00519	0.00604	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—ABCA1—glaucoma	0.00512	0.0363	CbGpPWpGaD
Trimetrexate—Fatigue—Acetazolamide—glaucoma	0.00512	0.00596	CcSEcCtD
Trimetrexate—Nausea—Methazolamide—glaucoma	0.0051	0.00594	CcSEcCtD
Trimetrexate—Thrombocytopenia—Pilocarpine—glaucoma	0.00504	0.00587	CcSEcCtD
Trimetrexate—Fatigue—Brimonidine—glaucoma	0.00492	0.00572	CcSEcCtD
Trimetrexate—Feeling abnormal—Acetazolamide—glaucoma	0.0049	0.0057	CcSEcCtD
Trimetrexate—Asthenia—Apraclonidine—glaucoma	0.00477	0.00555	CcSEcCtD
Trimetrexate—Pruritus—Apraclonidine—glaucoma	0.0047	0.00547	CcSEcCtD
Trimetrexate—Body temperature increased—Acetazolamide—glaucoma	0.0047	0.00547	CcSEcCtD
Trimetrexate—Fatigue—Dorzolamide—glaucoma	0.0047	0.00547	CcSEcCtD
Trimetrexate—Fatigue—Travoprost—glaucoma	0.00468	0.00544	CcSEcCtD
Trimetrexate—Asthenia—Bimatoprost—glaucoma	0.00462	0.00538	CcSEcCtD
Trimetrexate—Fatigue—Brinzolamide—glaucoma	0.00462	0.00537	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—SOD1—glaucoma	0.00457	0.0324	CbGpPWpGaD
Trimetrexate—Pruritus—Bimatoprost—glaucoma	0.00456	0.0053	CcSEcCtD
Trimetrexate—Feeling abnormal—Dorzolamide—glaucoma	0.00449	0.00522	CcSEcCtD
Trimetrexate—Feeling abnormal—Travoprost—glaucoma	0.00447	0.0052	CcSEcCtD
Trimetrexate—Feeling abnormal—Brinzolamide—glaucoma	0.00441	0.00514	CcSEcCtD
Trimetrexate—Body temperature increased—Dorzolamide—glaucoma	0.00431	0.00501	CcSEcCtD
Trimetrexate—Asthenia—Acetazolamide—glaucoma	0.00426	0.00496	CcSEcCtD
Trimetrexate—Feeling abnormal—Pilocarpine—glaucoma	0.00424	0.00494	CcSEcCtD
Trimetrexate—Vomiting—Apraclonidine—glaucoma	0.00422	0.00492	CcSEcCtD
Trimetrexate—Dermatitis—Apraclonidine—glaucoma	0.00418	0.00487	CcSEcCtD
Trimetrexate—Confusional state—Clonidine—glaucoma	0.00414	0.00482	CcSEcCtD
Trimetrexate—Asthenia—Brimonidine—glaucoma	0.00409	0.00476	CcSEcCtD
Trimetrexate—Body temperature increased—Pilocarpine—glaucoma	0.00407	0.00474	CcSEcCtD
Trimetrexate—Rash—Bimatoprost—glaucoma	0.00406	0.00473	CcSEcCtD
Trimetrexate—Dermatitis—Bimatoprost—glaucoma	0.00406	0.00472	CcSEcCtD
Trimetrexate—Anaemia—Betaxolol—glaucoma	0.00405	0.00472	CcSEcCtD
Trimetrexate—Pruritus—Brimonidine—glaucoma	0.00403	0.0047	CcSEcCtD
Trimetrexate—Thrombocytopenia—Clonidine—glaucoma	0.00402	0.00468	CcSEcCtD
Trimetrexate—Nausea—Apraclonidine—glaucoma	0.00395	0.00459	CcSEcCtD
Trimetrexate—Asthenia—Dorzolamide—glaucoma	0.00391	0.00455	CcSEcCtD
Trimetrexate—Asthenia—Travoprost—glaucoma	0.00389	0.00453	CcSEcCtD
Trimetrexate—Pruritus—Dorzolamide—glaucoma	0.00385	0.00449	CcSEcCtD
Trimetrexate—Asthenia—Brinzolamide—glaucoma	0.00384	0.00447	CcSEcCtD
Trimetrexate—Pruritus—Travoprost—glaucoma	0.00384	0.00447	CcSEcCtD
Trimetrexate—Nausea—Bimatoprost—glaucoma	0.00383	0.00445	CcSEcCtD
Trimetrexate—Pruritus—Brinzolamide—glaucoma	0.00379	0.00441	CcSEcCtD
Trimetrexate—Vomiting—Acetazolamide—glaucoma	0.00378	0.0044	CcSEcCtD
Trimetrexate—Asthenia—Pilocarpine—glaucoma	0.00369	0.0043	CcSEcCtD
Trimetrexate—Pruritus—Pilocarpine—glaucoma	0.00364	0.00424	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—MTHFR—glaucoma	0.00362	0.0257	CbGpPWpGaD
Trimetrexate—Confusional state—Betaxolol—glaucoma	0.00361	0.0042	CcSEcCtD
Trimetrexate—Rash—Brimonidine—glaucoma	0.0036	0.00419	CcSEcCtD
Trimetrexate—Dermatitis—Brimonidine—glaucoma	0.00359	0.00418	CcSEcCtD
Trimetrexate—Fatigue—Clonidine—glaucoma	0.00354	0.00412	CcSEcCtD
Trimetrexate—Nausea—Acetazolamide—glaucoma	0.00353	0.00411	CcSEcCtD
Trimetrexate—Thrombocytopenia—Betaxolol—glaucoma	0.0035	0.00408	CcSEcCtD
Trimetrexate—Vomiting—Dorzolamide—glaucoma	0.00346	0.00403	CcSEcCtD
Trimetrexate—Rash—Dorzolamide—glaucoma	0.00343	0.004	CcSEcCtD
Trimetrexate—Dermatitis—Dorzolamide—glaucoma	0.00343	0.00399	CcSEcCtD
Trimetrexate—Rash—Travoprost—glaucoma	0.00342	0.00398	CcSEcCtD
Trimetrexate—Dermatitis—Travoprost—glaucoma	0.00342	0.00398	CcSEcCtD
Trimetrexate—Vomiting—Brinzolamide—glaucoma	0.0034	0.00396	CcSEcCtD
Trimetrexate—Nausea—Brimonidine—glaucoma	0.00339	0.00394	CcSEcCtD
Trimetrexate—Feeling abnormal—Clonidine—glaucoma	0.00339	0.00394	CcSEcCtD
Trimetrexate—Rash—Brinzolamide—glaucoma	0.00338	0.00393	CcSEcCtD
Trimetrexate—Dermatitis—Brinzolamide—glaucoma	0.00337	0.00393	CcSEcCtD
Trimetrexate—Vomiting—Pilocarpine—glaucoma	0.00327	0.00381	CcSEcCtD
Trimetrexate—Body temperature increased—Clonidine—glaucoma	0.00325	0.00378	CcSEcCtD
Trimetrexate—Rash—Pilocarpine—glaucoma	0.00324	0.00378	CcSEcCtD
Trimetrexate—Dermatitis—Pilocarpine—glaucoma	0.00324	0.00377	CcSEcCtD
Trimetrexate—Nausea—Dorzolamide—glaucoma	0.00324	0.00377	CcSEcCtD
Trimetrexate—Nausea—Travoprost—glaucoma	0.00322	0.00375	CcSEcCtD
Trimetrexate—Nausea—Brinzolamide—glaucoma	0.00318	0.0037	CcSEcCtD
Trimetrexate—Fatigue—Betaxolol—glaucoma	0.00308	0.00359	CcSEcCtD
Trimetrexate—Nausea—Pilocarpine—glaucoma	0.00306	0.00356	CcSEcCtD
Trimetrexate—Asthenia—Clonidine—glaucoma	0.00295	0.00343	CcSEcCtD
Trimetrexate—Feeling abnormal—Betaxolol—glaucoma	0.00295	0.00343	CcSEcCtD
Trimetrexate—Confusional state—Timolol—glaucoma	0.00295	0.00343	CcSEcCtD
Trimetrexate—Pruritus—Clonidine—glaucoma	0.00291	0.00338	CcSEcCtD
Trimetrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—glaucoma	0.0029	0.0206	CbGpPWpGaD
Trimetrexate—Body temperature increased—Betaxolol—glaucoma	0.00283	0.00329	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CCND2—glaucoma	0.00272	0.0193	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—FGFR1OP—glaucoma	0.00266	0.0189	CbGpPWpGaD
Trimetrexate—Vomiting—Clonidine—glaucoma	0.00261	0.00304	CcSEcCtD
Trimetrexate—Rash—Clonidine—glaucoma	0.00259	0.00302	CcSEcCtD
Trimetrexate—Dermatitis—Clonidine—glaucoma	0.00259	0.00301	CcSEcCtD
Trimetrexate—Asthenia—Betaxolol—glaucoma	0.00257	0.00299	CcSEcCtD
Trimetrexate—Pruritus—Betaxolol—glaucoma	0.00253	0.00295	CcSEcCtD
Trimetrexate—Fatigue—Timolol—glaucoma	0.00252	0.00293	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle, Mitotic—RAB8A—glaucoma	0.0025	0.0178	CbGpPWpGaD
Trimetrexate—Nausea—Clonidine—glaucoma	0.00244	0.00284	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CDKN2B—glaucoma	0.00244	0.0173	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Timolol—glaucoma	0.00241	0.0028	CcSEcCtD
Trimetrexate—DHFR—Fluoropyrimidine Activity—TP53—glaucoma	0.00239	0.017	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—FGFR1OP—glaucoma	0.00238	0.0169	CbGpPWpGaD
Trimetrexate—Body temperature increased—Timolol—glaucoma	0.00231	0.00269	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—CDKN2A—glaucoma	0.00228	0.0162	CbGpPWpGaD
Trimetrexate—Vomiting—Betaxolol—glaucoma	0.00227	0.00265	CcSEcCtD
Trimetrexate—Rash—Betaxolol—glaucoma	0.00226	0.00263	CcSEcCtD
Trimetrexate—Dermatitis—Betaxolol—glaucoma	0.00225	0.00262	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—RAB8A—glaucoma	0.00224	0.0159	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—OPTN—glaucoma	0.00217	0.0154	CbGpPWpGaD
Trimetrexate—Nausea—Betaxolol—glaucoma	0.00213	0.00247	CcSEcCtD
Trimetrexate—Asthenia—Timolol—glaucoma	0.0021	0.00244	CcSEcCtD
Trimetrexate—DHFR—Metabolism—NARFL—glaucoma	0.00209	0.0149	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CA5A—glaucoma	0.00209	0.0149	CbGpPWpGaD
Trimetrexate—Pruritus—Timolol—glaucoma	0.00207	0.00241	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—CDKN1B—glaucoma	0.00202	0.0143	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—OPTN—glaucoma	0.00194	0.0138	CbGpPWpGaD
Trimetrexate—DHFR—Disease—LRP12—glaucoma	0.0019	0.0134	CbGpPWpGaD
Trimetrexate—Vomiting—Timolol—glaucoma	0.00186	0.00216	CcSEcCtD
Trimetrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—glaucoma	0.00185	0.0131	CbGpPWpGaD
Trimetrexate—Rash—Timolol—glaucoma	0.00184	0.00215	CcSEcCtD
Trimetrexate—Dermatitis—Timolol—glaucoma	0.00184	0.00214	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—CDKN1B—glaucoma	0.00175	0.0124	CbGpPWpGaD
Trimetrexate—Nausea—Timolol—glaucoma	0.00174	0.00202	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—TNF—glaucoma	0.00156	0.0111	CbGpPWpGaD
Trimetrexate—DHFR—G1/S Transition—CDKN1B—glaucoma	0.00146	0.0104	CbGpPWpGaD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CDKN2A—glaucoma	0.00139	0.00988	CbGpPWpGaD
Trimetrexate—DHFR—Folate Metabolism—TP53—glaucoma	0.00137	0.00975	CbGpPWpGaD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CDKN1B—glaucoma	0.00123	0.00875	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HEYL—glaucoma	0.00122	0.00866	CbGpPWpGaD
Trimetrexate—DHFR—Disease—FGFR1OP—glaucoma	0.00122	0.00866	CbGpPWpGaD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—glaucoma	0.0011	0.00782	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CA1—glaucoma	0.00102	0.00726	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CCND2—glaucoma	0.000997	0.00707	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CTSA—glaucoma	0.000991	0.00703	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CA2—glaucoma	0.000936	0.00664	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CDKN2B—glaucoma	0.000893	0.00634	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CCND2—glaucoma	0.000891	0.00632	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CDKN2B—glaucoma	0.000799	0.00567	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HDAC9—glaucoma	0.000762	0.00541	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—TXN—glaucoma	0.000659	0.00468	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GSTT1—glaucoma	0.000511	0.00363	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—glaucoma	0.000511	0.00362	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CDKN2A—glaucoma	0.000457	0.00324	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CDKN1B—glaucoma	0.000452	0.00321	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CDKN2B—glaucoma	0.00041	0.00291	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—ABCA1—glaucoma	0.000407	0.00289	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYP1B1—glaucoma	0.000407	0.00289	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CDKN1B—glaucoma	0.000405	0.00287	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MTHFR—glaucoma	0.000344	0.00244	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—GSTM1—glaucoma	0.000326	0.00231	CbGpPWpGaD
Trimetrexate—DHFR—Disease—APOE—glaucoma	0.00032	0.00227	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CAV1—glaucoma	0.000317	0.00225	CbGpPWpGaD
Trimetrexate—DHFR—Disease—BAD—glaucoma	0.000298	0.00211	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—MTHFR—glaucoma	0.000288	0.00204	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—APOE—glaucoma	0.000268	0.0019	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CAV1—glaucoma	0.000265	0.00188	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—TP53—glaucoma	0.000254	0.0018	CbGpPWpGaD
Trimetrexate—DHFR—Disease—NOS3—glaucoma	0.00024	0.0017	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PTGS2—glaucoma	0.000219	0.00155	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CDKN1B—glaucoma	0.000208	0.00147	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—NOS3—glaucoma	0.000201	0.00142	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PTGS2—glaucoma	0.000184	0.0013	CbGpPWpGaD
